Dr. Glynn is, from 2014 to the present, Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine and Executive Team Member, Mayo Clinic Global Bridges Initiative. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS).   Prior to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute's (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI's Cancer Control Extramural Research Branch.. From 1983 to 1991, he was Research Director for the NCI's Smoking, Tobacco, and Cancer Program and from 1978 to 1983, he was a Research Psychologist at the National Institute on Drug Abuse.   Dr. Glynn has published widely on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education. In addition to his work at the ACS and NCI, he has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, the WHO, a variety of pharmaceutical organizations, and national, state and local governments.   He has also served as a Senior Scientific Reviewer for the U.S. Surgeon General's Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. He is a Fellow of the Society for Research on Nicotine and Tobacco and his awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the Society for Research on Nicotine and Tobacco John Slade Award, and the American Society of Preventive Oncology Joseph W. Cullen Memorial Award.  

Benjamin Apelberg, PhD is the Deputy Director for Regulatory Science in the Office of Science at FDA’s Center for Tobacco Products (CTP). In this role, he oversees scientific divisions responsible for managing the Office’s tobacco regulatory science research program, including the Population Assessment of Tobacco and Health (PATH) study and collaboration with CDC on the National Youth Tobacco Survey; serving as expert reviewers and technical project leads (TPLs) for the premarket tobacco product application (PMTA) and modified risk tobacco product application (MRTPA) pathways; and providing scientific expertise in the fields of the health sciences, medicine, pharmacology, epidemiology, social science, evaluation, and statistics to support the Center’s tobacco product regulatory efforts.

Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the National Institute for Health and Care Excellence committee which developed guidance for England on tobacco harm reduction and of an expert advisory group to the UK’s medicines regulator the MHRA on e-cigarettes.  She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes. Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group.  She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health. Competing Interest: None Stated

Clive Bates has had a diverse career in the public, private and not-for-profit sectors.  He started out with the IT company, IBM, then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.

Neal L. Benowitz, MD, is Emeritus Professor of Medicine in the Research Program in Clinical Pharmacology, Division of Cardiology, at the University of California, San Francisco (UCSF). He was Chief of the Division of Clinical Pharmacology and Experimental Therapeutics at UCSF for 35 years. He received his medical degree from the University of Rochester School of Medicine in 1969, following which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 800 research papers. Dr Benowitz maintains an active clinical practice in cardiovascular medicine and medical toxicology. Dr Benowitz was a scientific editor of the 1988 United States Surgeon General’s Report on Smoking and Health: Nicotine Addiction; a scientific editor of the 2001 NCI Monograph 13 Report on Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine; and served as section editor for the 2010 Surgeon General’s Report on How Tobacco Smoke Causes Disease. He, has served as a member of the National Institutes of Health Pharmacology Study Section and the FDA Nonprescription Drug and Tobacco Products Science Advisory Committees. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.  

Dr. Matthew Carpenter holds the Flora McLeod Edwards Distinguished Endowed Chair in Cancer Research and is Professor within the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina, where he also serves as co-leader of the Cancer Control Program of the Hollings Cancer Center. Dr. Carpenter’s research interests relate to tobacco use across a broad methodological continuum: from lab-based studies of produce reinforcement and nicotine dependence, to small and large scale clinical trials for smoking cessation and cessation induction, to public health  policy for effective tobacco control. He has led multiple studies and trials of alternative tobacco products. He has served on a number of NIH study sections, including several as Chair. He is currently a standing member of the NIH CSR Advisory Council. Dr. Carpenter has mentored a number of junior investigators across various grant mechanisms, and regularly accepts new trainees at either pre- or postdoctoral levels. Dr. Carpenter holds a PhD in Clinical Psychology from the University of Vermont.

Alex comes from a background in customer service and logistics. Shortly after discovering the value of Tobacco Harm Reduction, he began volunteering his time for CASAA and was appointed to serve on CASAA’s Board of Directors in 2014, and later that same year was elected as CASAA’s Legislative Director. Alex stepped down from the Board of Directors in January 2016 in order to accept a position as CASAA’s Legislative Coordinator and was promoted by the Board to CEO in March 2017. Alex is responsible for overseeing all of CASAA’s advocacy efforts.

Kathleen Crosby is currently Director of the Office of Health Communication and Education at the FDA Center for Tobacco Products (CTP). The office is responsible for conducting public education, stakeholder outreach, and regulatory communication programs designed to ensure FDA's success in implementing the Tobacco Control Act. These efforts include developing breakthrough communication strategies to reduce youth tobacco use, helping current tobacco users quit, and building stakeholder understanding of and compliance with FDA tobacco product regulations. Since joining CTP in February 2011, Ms. Crosby has led the development and implementation of multiple public education campaigns targeting at-risk and underserved populations, including FDA's first-ever national youth tobacco prevention campaign, "The Real Cost." From its launch in Feb. 2014 to Nov. 2016, the award-winning campaign has prevented up to 587,000 youth ages 11 to 19 from initiating smoking, half of whom might have gone on to become established adult smokers. Ms. Crosby's career spans 20 years of senior-level marketing and advertising experience working on large-scale multimedia campaigns and education programs for major national brands in both the private and non-profit sectors. Before beginning at CTP, Ms. Crosby was Senior Vice President, Group Campaign Director of the Washington office of the Ad Council, where she successfully managed day-to-day operations. In her nine years at the Ad Council, she created integrated communication programs that have proven to inspire attitudinal and behavioral change for America's most pressing social issues. One of Ms. Crosby's leadership roles at the Ad Council was as Campaign Director for 17 United States government agencies, including the Departments of Health and Human Services, Transportation, Homeland Security, Energy, Defense, Agriculture, and Justice. Previously, while serving as Vice President of Strategic Planning at Arnold Worldwide, Ms. Crosby oversaw the strategic development of the Legacy Foundation's "Truth" campaign, which is widely regarded as one of the most potent and successful tobacco prevention campaigns ever conducted in the United States. Ms. Crosby received a B.A. degree from University of Colorado in Political Science with a minor in Spanish.

Cliff Douglas is the Director of the University of Michigan Tobacco Research Network, an adjunct professor at the School of Public Health, and a co-principal investigator for the Center for the Assessment of Tobacco Regulations at the University of Michigan. He was the American Cancer Society’s Vice President for Tobacco Control from 2015 to 2020, where he led the development of a comprehensive new public health approach to tobacco control, set forth in the American Cancer Society Public Health Statement on Ending Combustible Tobacco Use in the United States (2018), and co-founded the National Partnership on Behavioral Health and Tobacco Use, which is dedicated to increasing cessation and reducing mortality and illness in smokers with mental health conditions. He also provided expertise on issues related to the changing tobacco product marketplace and guided ACS’s efforts to educate the public about the impact of smoking on COVID-19. Previously, he served as a policy advisor for the Assistant Secretary for Health and the U.S. Surgeon General in the Obama administration, where he was a lead author of the Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services. Earlier in his career, he coordinated the successful national campaign to make all commercial airline flights smoke-free and participated as an attorney and public health expert in the litigation that resulted in adoption of the Master Settlement Agreement. As special counsel for Congressman Martin Meehan and the Congressional Task Force on Tobacco and Health in the U.S. House of Representatives, he wrote legislation and prepared the 111-page prosecution memorandum that persuaded the U.S. Attorney General to launch a criminal investigation into the tobacco industry and later file the Justice Department’s landmark racketeering (RICO) action against the major tobacco companies. As told in Civil Warriors: The Legal Siege on the Tobacco Industry, Mr. Douglas also helped tobacco industry whistleblowers go public, and initiated an ABC News expose on the tobacco companies’ engineering of their products to cause dependency that led the Food and Drug Administration to open a two-year investigation and regulate tobacco for health and safety for the first time.

Dr. Jonathan Foulds has spent most of his career finding ways to help smokers beat their addiction to tobacco. He has been a principal investigator on grants totaling well over $27 million and has been invited to speak on smoking cessation in more than 15 countries. In addition to his many publications on tobacco in peer-reviewed scientific journals, Dr Foulds continues to teach on smoking cessation and conduct research on electronic cigarettes and other reduced harm nicotine products.  

Abigail S. Friedman is an Associate Professor in the Department of Health Policy and Management at the Yale School of Public Health. Her research focuses on the policy determinants of tobacco use and disparities therein, with the overarching goal of informing and facilitating evidence-based policymaking to improve population health and reduce inequality. A health economist by training, she conducts work in three areas. The first uses quasi-experimental methods to estimate the effects of federal, state, and local policies on conventional and electronic cigarette use, in order to inform more nuanced policymaking that accounts for the differing health impacts of these products. The second line of research considers how new tobacco products and policies are affecting disparities in tobacco use, particularly by socioeconomic status and mental health. Finally, her work on mental health disparities in tobacco use focuses on identifying the drivers behind these differentials as well as potential means to close these gaps, particularly among adolescents and young adults. Dr. Friedman received her undergraduate degree from Columbia University and her Ph.D. in the economics concentration of Harvard University’s Ph.D. Program in Health Policy.  

Professor of Oncology, Department of Health Behavior, Division of Cancer Prevention and Population Studies Roswell Park Comprehensive Cancer Center Biography Dr. Maciej L. Goniewicz joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2013 as Assistant Member of the Department of Health Behavior, Division of Cancer Prevention and Population Sciences. In 2016, he was appointed Associate Member and as a Full Member in 2021. He is a Director of the Nicotine and Tobacco Product Assessment Resource (NicoTAR; www.nicotar.org). He earned a Pharm.D. degree (2002) and a Ph.D. in Toxicology and Pharmacology (2007) from the Medical University of Silesia, Poland. He completed his postdoctoral fellowships in Clinical Pharmacology and Tobacco Control at the University of California San Francisco and in Smoking Cessation Treatment in Queen Mary University of London, UK. Dr. Goniewicz has authored over 200 scientific papers on topics related to tobacco control, biomarkers, and nicotine-containing products. His work has been published in NEJM, JAMA, Annals of Internal Medicine, Lancet Respiratory Medicine, Tobacco Control, Nicotine and Tobacco Research, Pediatrics, Chemical Research in Toxicology, Journal of Analytical Toxicology, and Cancer Epidemiology, Biomarkers, and Prevention.

Peter Hajek is Professor of Clinical Psychology and Director of the Tobacco Dependence Research Unit at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. His research is concerned primarily with understanding health behaviours, and developing and evaluating both behavioural and pharmacological treatments for dependent smokers and for people with weight problems. Professor Hajek is a member of a number of expert groups, advisory bodies and editorial boards, and has authored or co-authored over 350 publicatio

Jamie Hartmann-Boyce is Associate Professor and departmental lecturer with the Centre for Evidence-Based Medicine at the Nuffield Department of Primary Care Health Sciences, University of Oxford. Her particular interests lie in evidence synthesis (both quantitative and qualitative) and the communication of complex information and data to inform policy and public action. Her research mainly consists of complex evidence synthesis work. She leads the Cochrane review of electronic cigarettes for smoking cessation, which is now a living review funded by Cancer Research UK, updated monthly, and is an editor for the Cochrane Tobacco Addiction Group.

Andrew Hyland is the Chair of the Department of Health Behavior at Roswell Park Comprehensive Cancer Center and the Scientific Principal Investigator of the Population Assessment of Tobacco and Health (PATH) Study, which is supported by the National Institute on Drug Abuse and the Food and Drug Administration to study more than 46,000 adults and children nationally over a 14 year period to understand changes in tobacco use behaviors and health. Dr. Hyland’s research program is focused on providing an evidence base to inform policies, regulations, and interventions to reduce the disease burden caused by tobacco by as much and to as many people as quickly as possible.  He has conducted numerous funded clinical and population-based studies, published more than 380 papers, and has been recognized for his service and scholarship by both local and international agencies.

Dr. Sonia Johnson is the Director General of the Tobacco Control Directorate at Health Canada. In this role, she is responsible for leading Canada’s Tobacco Strategy, which aims to reduce tobacco use to less than 5% by 2035 using bold and innovative measures to help people quit tobacco while preventing a new generation from nicotine addiction. This includes effective regulation of vaping products under the Tobacco and Vaping Products Act, to prevent youth use of these products while maintaining legal access for adults to switch completely from tobacco to vaping. During her 20 year career at Health Canada, Dr. Johnson has managed several science and research teams, and has emphasized the importance of providing the scientific evidence base to inform government policies, regulations and public education and outreach initiatives. She has a PhD in Chemistry from the University of Ottawa

Dr. Brian King was appointed Director of the Food and Drug Administration’s Center for Tobacco Products (CTP) in July 2022. In this position, Dr. King is responsible for assuring that CTP accomplishes its public health goals and for operationalizing the Center’s vision and mission as it implements the Family Smoking Prevention and Tobacco Control Act. Dr. King has worked for nearly two decades to provide sound scientific evidence to inform tobacco control policy and to effectively communicate this information to key stakeholders, including decision makers, the media, and the general public. Prior to joining FDA, he served as the Deputy Director for Research Translation in CDC’s Office on Smoking and Health, and more recently as the Executive Editor of CDC’s Morbidity & Mortality Weekly Report Series. He has authored more than 200 scientific journal articles related to tobacco prevention and control, served as Senior Associate Editor for multiple U.S. Surgeon General’s Reports on tobacco, and was lead author of CDC’s 2014 evidence-based guide, “Best Practices for Comprehensive Tobacco Control Programs.” Dr. King holds a Ph.D. and M.P.H. in Epidemiology from the State University of New York at Buffalo.

David Levy has a PhD in Economics from UCLA and is currently a Professor of Oncology at Georgetown. He has published over 300 papers, including articles in the American Economic Review, American Journal of Public Health, JAMA, Lancet, Medical Care, American Journal of Preventive Medicine, Tobacco Control, Nicotine and Tobacco Research and the Review of Economics and Statistics. His work spans topics in public health and industry behavior.  Dr. Levy has been the principal investigator of grants from the Centers for Disease Control and Prevention, the World Health Organization, the National Cancer Institute, the National Institute on Drug Abuse, Bloomberg/Gates Foundation, European Union, and the Robert Wood Johnson Foundation.  He is currently the principal investigator of an FDA TCORS, and is a principal investigator on grants from the National Cancer Institute to the ITC project and to the CISNET Lung group.  Dr. Levy oversees the design and development of the SimSmoke tobacco policy simulation model, which predicts the effect of tobacco policies, such as tax increases, smoke-free air laws, media campaigns, youth access policies, and cessation treatment policies, on smoking rates and tobacco-related deaths. He has developed models for 12 states and more than 60 countries. A version of the SimSmoke that incorporated the use of smokeless tobacco. He is currently developing simulation models that incorporate the use of e-cigarettes, including his most recent Smoking and Vaping Model (SAVM).

Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998. She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies. Competing Interest: None Stated

Robin Mermelstein, PhD. is Distinguished Professor, Psychology Department; Director of the Institute for Health Research and Policy at the University of Illinois at Chicago (UIC), and Co-Director of UIC’s Center for Clinical and Translational Science.  Dr. Mermelstein has been active in health-behavior research for 30 years, with continuous NIH funding as a Principal Investigator on grants since 1986. Dr. Mermelstein was acknowledged by the NCI as a Research Pioneer in the Division of Cancer Control and Population Sciences. She is nationally recognized for her expertise in understanding trajectories and developmental patterns of youth tobacco use, for employing novel approaches to studying contextual factors in the development of nicotine dependence and health risk behaviors, for developing innovative health behavior clinical interventions for adolescents and adults, and for methodological issues in conducting tobacco-related research. She has been the PI of several large-scale, multidisciplinary program project and center grants, as well as the Director of a national program or the Robert Wood Johnson Foundation. Dr. Mermelstein has served on many NIH advisory and review committees, including being a former standing member of the NCI-A Cancer Centers review committee; a former member of the External Scientific Advisory Panel for the NCI’s Science of Research and Technology Branch; co-Chair of the NCI’s Tobacco Control Priorities Consultant Group; a former standing member of the National Institute on Drug Abuse’s K-award study section; and a current member of the External Scientific Advisory Board for the Adolescent Brain and Cognitive Development Study (ABCD Study) of NIH. She has been acknowledged for her scientific accomplishments by several national and international research societies, including being named a Fellow of the Association of Psychological Science, a Fellow of the Society of Behavioral Medicine, and a Fellow of the Society for Research in Nicotine and Tobacco. She is a past President of the Society for Research on Nicotine and Tobacco (2015-2016).  

The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.

Dr. Niaura is a Professor of Social and Behavioral Health at NYU GPH and the Co-Director of the Tobacco Research Lab. His research interests are two-fold: studying the bio-behavioral substrates of tobacco dependence, including factors that influence adolescent and early adult tobacco use trajectories; and evaluating behavioral and pharmacological treatments for cessation, specifically with regard to addressing public health disparities in tobacco related burdens of illness and disability. He comes to NYU from the Washington, DC-based Schroeder Institute (SI) for Tobacco Research and Policy Studies where he was Director of Science and Training for eight years. Dr. Niaura has extensive expertise in tobacco dependence and treatment, having published over 400 peer-reviewed articles, commentaries and book chapters in this field. He has been PI or co-I of over 70 NIH-funded grants and is the former President of the Society of Nicotine and Tobacco Research.

Nancy Rigotti, MD, is a Professor of Medicine at Harvard Medical School, Associate Chief of the Division of General Internal Medicine at Massachusetts General Hospital (MGH), founder and director of MGH’s Tobacco Research and Treatment Center, as well as Past President of the Society for Research in Nicotine and Tobacco and Past President of the Society of General Internal Medicine.  Dr. Rigotti is known for her leadership to incorporate the delivery of tobacco use treatment into routine health care delivery settings. She led JAMA’s 2022 Clinical Review, Treatment of Tobacco Use and co-led the American College of Cardiology’s Consensus Decision Pathway on Tobacco Cessation Treatment. Her research includes evaluations of tobacco control public policies, clinical trials of behavioral and pharmacologic smoking cessation treatments, and evaluation of system-level interventions for various inpatient and outpatient health care settings in the U.S. and globally. Dr. Rigotti was a member of the committee that produced the 2018 U.S. National Academies of Science, Engineering, and Medicine Report, Public Health Consequences of Electronic Cigarettes.  Her subsequent research on this topic has addressed the role of e-cigarettes for smoking cessation and harm reduction and interventions to assist e-cigarette users to quit.

Kenneth E. Warner is the Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus at the University of Michigan School of Public Health. A member of the faculty from 1972-2017, he served as Dean from 2005-2010. Presented in over 300 professional publications, Dr. Warner’s research has focused on economic and policy aspects of tobacco and health. Dr. Warner served as the World Bank’s representative to negotiations on the Framework Convention on Tobacco Control. He also served as the Senior Scientific Editor of the 25th anniversary Surgeon General’s report on smoking and health. From 2004-2005 he was President of the Society for Research on Nicotine and Tobacco (SRNT). He recently completed a term on the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee. He is an elected member of the Board of Trustees of Northwestern Michigan College. In 1996 Dr. Warner was elected to the National Academy of Medicine. Among other honors and awards, he is a recipient of the Surgeon General’s Medallion, the Luther Terry Award for Exemplary Achievement in Tobacco Control, and the Doll-Wynder Award from SRNT. Dr. Warner earned his AB from Dartmouth College and MPhil and PhD in economics from Yale University.  

Ben Youdan has campaigned professionally for nearly 20 years, and has over a decade of experience leading charitable organisations in the UK and New Zealand. His career has taken us from running the biggest health awareness day in the UK, to setting up a major community initiative in south Auckland. He's run government funded social marketing programmes the UK and New Zealand, headed political campaign teams and been a regular media commentator.  He moved to New Zealand in 2006 to run ASH, where he campaigned for the Smokefree 2025 goal. He left ASH in 2013 to lead the election campaign for the Green Party where he overhauled the campaign systems, delivering the biggest ever ground campaign in the Party’s history.  

Mitch Zeller, J.D., was the director of the FDA’s Center for Tobacco Products from March 2013 through April 2022. The mission of CTP—established by enactment of the 2009 Family Smoking Prevention and Tobacco Control Act—is “to make tobacco-related death and disease part of America’s past, not America’s future, and, by doing so, ensure a healthier life for every American family.”  As Center Director, Zeller led FDA’s efforts to use the tools of product regulation to reduce disease and death from tobacco use and bring previously unavailable information about its dangers to light. Zeller, a graduate of Dartmouth College and the American University Washington College of Law, worked on FDA issues from 1982 until his retirement in 2022. He began his career as a public interest attorney in 1982 at the Center for Science in the Public Interest (CSPI). In 1988, Zeller left CSPI to become counsel to the Human Resources and Intergovernmental Relations Subcommittee of the House of Representatives Government Operations Committee where he conducted oversight of enforcement of federal health and safety laws. In 1993, Zeller joined the staff of then-FDA Commissioner Dr. David Kessler, M.D. What began as a two-week assignment by Kessler in 1994 to examine the practices of the tobacco industry led to his serving as associate commissioner and director of FDA’s first Office of Tobacco Programs. Instrumental in crafting the agency’s 1996 tobacco regulations, Zeller also represented FDA before Congress, federal and state agencies. Zeller also served as an official U.S. delegate to the World Health Organization (WHO) Working Group for the Framework Convention on Tobacco Control. In 2000, Zeller left FDA to continue his work for tobacco control as executive vice president of the American Legacy Foundation. His responsibilities there included marketing, communications, strategic partnerships, and creating the foundation’s first Office of Policy and Government Relations. In 2002, Zeller joined Pinney Associates where, as senior vice president, he provided strategic planning and communications advice on domestic and global public health policy issues involving the treatment of tobacco dependence and the regulation of tobacco products and pharmaceuticals.  He left Pinney Associates in 2013 upon his return to FDA as Center Director. Mitch Zeller currently serves as an advisor to Qnovia, Inc. a start-up pharmaceutical company developing an inhaled smoking cessation product that it intends to seek FDA authorization for marketing.